OxfordBiomedica

Home
About
Oxford BioMedica is one of the leading companies in gene therapy and immunothera…
- Mission and strategy
  Our mission is to build a financially self-sustaining company based on the succe…
- History
  From Oxford University spin out to one of the leading companies in gene and immu…
- Meet the team
- Careers
  Oxford BioMedica develops gene-based medicines for the treatment of cancer, neur…
- FAQ
  In this section we have provided answers to some of the most commonly asked ques…
- Meet us
  The management team regularly attends key industry conferences to meet investors and potential partners. Our scientists also represent Oxford BioMedica at key scientific and medical congresses.
R&D
We have core in-house expertise in genetic engineering techniques and cancer immunology. Through scientific innovation, we have established a platform of unique technologies.
- What is gene therapy?
  Gene therapy is a technique which arms the body with its own biological ammunition to fight disease.
- Pipeline
- Platform technologies
  - The LentiVector^® platform
    Oxford BioMedica’s proprietary gene delivery system, called the LentiVector® platform technology, was invented through pioneering work initially at Oxford University and then through in-house development. Pre-clinical and clinical studie…
  - 5T4 Tumour Antigen
    The 5T4 tumour antigen is a unique protein found on most common types of solid cancer, which makes it a potentially valuable target for novel anti-cancer interventions. The 5T4 antigen was discovered by scientists at Cancer Research UK (for…
- Products
- Clinical trials
  Oxford BioMedica is currently recruiting for clinical trials as detailed below. For further information, please visit the www.clinicaltrials.gov website or contact your doctor or primary healthcare professional. If you are currently par…
- Key publications
  Below is a selection of key publications of interest. A more comprehensive list can be provided on request.
Partnerships
Our strategy is to maximise the potential of our technologies and product candid…
- Current partnerships
  - Our partners
  - Our licensees
- Opportunities
  Oxford BioMedica is seeking development and commercialisation partners for the following products. Click on each product for more information.
- Intellectual property
  Oxford BioMedica has built an extensive patent portfolio that provides comprehensive protection for gene-based delivery technologies and their therapeutic application. This portfolio contains over fifty patent families which are either own…
Manufacturing
Oxford BioMedica is a world leader in the development of lentiviral vector-based…
Investors
Oxford BioMedica has strong fundamentals as an investment proposition. We have an exciting development pipeline and a commercially focused management team. Our achievements so far demonstrate our ability to deliver operational progress. We…
- Analyst coverage
  The following analysts cover Oxford BioMedica:
- Key financial information
- Share price information
  - Share price chart
- Regulatory news
- Shareholder meetings
- Corporate governance
  The policy of the Board is to manage the affairs of Oxford BioMedica to the high…
  - Board committees
- Warning to shareholders
  In recent years, many companies have become aware that their shareholders have received unsolicited phone calls or correspondence concerning investment matters. These are typically from overseas based ‘brokers’ who target UK shareholder…
- Investor contacts
- Financial calendar
- Registrars
  All administrative enquiries relating to shareholdings and requests to receive corporate documents by email should, in the first instance, be directed to Capita Registrars.
- Financial reports
Media
- Press releases
- Download centre
- Contacts and notes
  For more information, please contact our Communications team at enquiries@oxfordbiomedica.co.uk
- Glossary
- In the news
  We provide this list for your convenience only and do not endorse or express any opinion on these articles. The list will be updated on a regular basis, but does not purport to be complete, correct or representative as of any point in time.
CSR
At Oxford BioMedica we recognise our obligation to behave as a responsible corpo…
Contact

Ophthalmology is a high growth market estimated to be worth €16bn worldwide by 2016

As confidence in gene therapy grows, we are well-positioned to fight ocular disease with the next generation of high value gene-based medicines

Our capabilities cover the entire product lifecycle

From pre-clinical development, to regulatory support, to all future stages of clinical development and specialist manufacturing. With multiple opportunities ahead, our highly-experienced management team is resolutely focused on leading our evolution

Our pioneering technology has inspired powerful industry alliances

We are privileged to be working alongside global pharmaceutical players, professors, academic institutions, charitable organisations and industry specialists within our chosen fields of development

Investor centre

Presentations Pipeline FAQ

News
Twitter

Oxford BioMedica Interim Management Statement
16 May 2013
Oxford BioMedica Announces Update from ARVO 2013
9 May 2013
Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing Collaboration
1 May 2013

More news

Having extended financial resources into Q2 2014 we remain confident in our ability to deliver our strategic goals http://t.co/uw5ehWz97X

16th May, 2013 06:10am
John Dawson CEO: "We have made a strong start to 2013 having secured a revenue-generating lentiviral vector manufacturing alliance" #biotech

16th May, 2013 06:07am

Quick links

Legal

Cookies

This website uses cookies to improve user experience. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. Read more about our cookie policy here.

Follow us

Oxford BioMedica plc

Medawar Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford OX4 4GA
United Kingdom

Telephone: +44 (0) 1865 783 000
Fax: +44 (0) 1865 783 001
Email: enquiries@oxfordbiomedica.co.uk

Website by thinkerdoer

twitter linkedin youtube flickr RSS email